Back to Authors

investigators, on behalf of the INBUILD trial

A5059210153

Mayo Clinic

No affiliation available

Citations 2

Efficacy and Safety of Nintedanib in Elderly Patients with Progressive Fibrosing Interstitial Lung Diseases (ILDs)

B22. EMERGING MANAGEMENT OF FIBROTIC ILDs | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A2426-A2426

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2426

Effects of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases (ILDs) Taking Anti-Acid Therapy

TP28. TP028 APPROACH TO THERAPY IN FIBROSING AND NON-FIBROSING ILD | May 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: A1906-A1906

10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1906